Encephalitis characterized by antibodies against leucine-rich, glioma-inactivated 1 (LGI1) is the second most frequent AIE. Infections (parainfectious) are frequent triggers of encephalitis. While the majority of patients with AIE present with clinical symptoms, involuntary movements, altered level of consciousness, impaired memory and cognition, psychiatric symptoms, and seizures, it is important to acknowledge that patients with AIE may present seronegative cerebrospinal fluid (CSF) and therefore antibody testing is not pathognomonic.

AIE may present a range of clinical features including behavioural changes, impaired memory and cognition, psychiatric symptoms, involuntary movements, altered level of consciousness and seizures. Tumours (paraneoplastic) and infections (parainfectious) are frequent triggers of encephalitis.

Because of the similarities in the clinical, imaging and laboratory findings with viral encephalitis, the diagnosis of AIE is rather challenging and physicians require increased awareness and clinical acumen to make the correct diagnosis.

AIE was not described until 2007 because of the lack of specific clinical symptoms, laboratory, and magnetic resonance imaging (MRI) results. When these three parameters are combined, as shown in this case report, the diagnosis of definite AIE can be made, enabling specific therapeutic interventions that if performed at an early stage can significantly improve the outcome. It is important to acknowledge that patients with AIE may present seronegative cerebrospinal fluid (CSF) and therefore antibody testing is not pathognomonic.

CASE PRESENTATION
A 35-year-old healthy male, without any significant past medical history presented at the emergency department with a chief complaint of altered level of consciousness and seizures. He had a history of headaches for one year and a family history of seizures. The patient had no significant past medical history.

He was admitted to the hospital with a diagnosis of AIE. The diagnosis was made based on the presence of clinical symptoms, laboratory, and magnetic resonance imaging results.

Autoantibodies were not detected in the cerebrospinal fluid (CSF) and the patient was treated with immunotherapy. The patient showed significant improvement and was discharged from the hospital in a few days.

Keywords: Autoantibodies; Encephalitis/diagnosis; Encephalitis/diagnostic imaging; Immunotherapy
(ED) in January 2019 with behaviour disturbances in the previous five days and speech disturbances in the previous twenty-four hours. There was a suspicion that he had a seizure coming to the ED. No sphincter incontinence or tongue biting was noticed. In the previous five days, he had been experiencing periods of confusion, sweating, and fainting sensation from which he spontaneously recovered. There was no prior history of seizures, loss of consciousness, or drug use. Simultaneously, he had an unintentional weight loss of 10 kg in eight months, anorexia, and vomiting.

Physical examination was normal. On neurological examination, he was awake and presented global aphasia (non-fluent speech, he was unable to repeat words or to follow commands), without any other focal neurologic deficits. There were no meningeal signs. Brain computed tomography (CT) was normal. The electroencephalography (EEG) revealed a probable complex partial status epilepticus (frequent left frontotemporal paroxysmal activity). The MRI showed a hyperintense signal on T2-weighted/FLAIR on the medial left temporal lobe (Fig. 1).

CSF showed pleocytosis (47 cells) with mononuclear predominance and elevated proteins (67 mg/dL). The suspicion of a seizure combined with the MRI hyperintense signal on the left temporal lobe was suggestive of herpes simplex encephalitis (HSE).

He was first treated with phenytoin 750 mg IV for reversal of status epilepticus and then started a 21-day cycle of acyclovir 750 mg 8/8 hours for presumed HSE. The microbiological study of CSF was unremarkable (polymerase chain reaction (PCR) with both negative serology and bacteriological study – HSV-1, HSV-2, HHV-3, Epstein-Barr virus, cytomegalovirus, HHV-6, HHV-7, HHV-8 negative). Lumbar puncture was not repeated, but lumbar puncture (LP) was performed three days after onset of symptoms. Blood cultures were also negative. He experienced considerable improvement with medication (recovery of normal behaviour and speech) and besides experiencing persecutory delusions while in the hospital, he was released with sporadic speech disorder and without full recovery of cognitive functions. There was a reversal of the imaging changes after treatment.

In July, six months later, he presented in the ED with behavioural and speech changes associated with right hemiparesis in the past 24 hours. His wife mentioned episodes of mental confusion and speech changes since his previous hospitalization. He also showed sudden impairment of consciousness (not reactive to stimuli), right arm clonic movements, and oculocephalic deviation to the right. He received antiepileptic treatment with slight improvement. The EEG was consistent with a complex partial status epilepticus (left temporal paroxysmal activity). Since the status epilepticus was refractory to the antiepileptic medication administered in the ED, he was transferred to the intensive care unit (ICU).

The brain CT showed a hypodensity in the left frontoparietal region. The MRI showed a hyperintense T2/Flair signal in the left frontoparietal and occipital region (Fig. 2). The lumbar puncture performed on the same day of the hospitalization showed CSF with mildly elevated proteins (71 mg/dL), mononuclear cells (25 cells) negative bacteriological examination, negative serologies, and negative cytology for neoplastic cells. The LP was repeated and showed clear and colourless CSF with mononuclear cells (seven cells)

Figure 1 – MRI in February 2019 showed hyperintense signal on T2/FLAIR on the medial left temporal lobe in coronal and axial planes, respectively
and proteins (0.7 mg/dL), negative serology, bacteriological, and mycological examination. The autoimmune study was negative for anti VGKC, anti-NMDAR, anti-GABAa-R, anti-GABAb-R, anti-LGI1, anti- Ma2/Ta, anti-GAD, anti-MAG, anti-Hu and anti- CV2 (immunoblotting and indirect immunofluorescence assay). The diagnostic study in blood culture, urine culture and CSF (PCR) was negative for HSV-1, HSV-2, HHV-3, Epstein-Barr virus, cytomegalovirus, HHV-6, HHV-7, Enterovirus, Treponema pallidum, HBV, HIV, HTLV, Mycobacterium tuberculosis, Borrelia burgdorferi, tick-borne encephalitis virus (TBEV), Anaplasma phagocytophilum, Ehrlichia chaffeensis/ Ehrlichia muris, human polyomavirus 2 (JC), polyomavirus BK.

To exclude paraneoplastic causes, a thoracoabdominal pelvic CT scan was performed, with no relevant alterations.

In the ICU he was treated first with a 5-day cycle of high-dose methylprednisolone with a progressive reduction in oral dose associated with a 5-day cycle of immunoglobulin. Simultaneously, he also received a 21-day cycle of acyclovir. He was also treated for a urinary tract infection with amoxicillin and clavulanic acid. He progressively showed some slight improvements in speech and motor functions (ability to follow commands, articulate words, and phrases, improved spatial and self-orientation), with successful treatment of the complex partial status epilepticus. The patient was released in August with antiepileptic medication (levetiracetam, lacosamide, and clobazam) and periodic appointments to assess the mental status and investigate a possible paraneoplastic cause.

On a follow-up clinic in November, although maintaining normal speech and motor functions, he had a clear limitation in time, spatial, and self-orientation and showed considerable memory loss with implications in daily life activities. He presented a score of five in the Montreal Cognitive Assessment (MoCA).

**DISCUSSION**

This case presents the challenges of diagnosing AIE, since the patient, despite having the typical clinical presentation and imaging findings consistent with AIE, had negative results for antibodies in blood and CSF. Such cases can be misdiagnosed as viral encephalitis. This case report highlights the importance of considering the hypothesis of autoimmune aetiology on the differential diagnosis of all patients presenting with clinical and MRI results suggestive of probable encephalitis regardless of the negative antibody results. Confirmatory antibody testing should be required, but a negative result does not exclude the diagnosis, especially if other possible causes are excluded. The diagnostic criteria for the different types of AIE were published by Graus et al in 2016.

The hypothesis of autoimmune encephalitis after herpes simplex encephalitis (post-herpetic anti-NMDA encephalitis) should be considered. In fact, a prospective observational study showed that 27% of patients present with AIE after HSE. These patients developed neuronal antibodies (100%), usually within two months after treatment of HSE. Therefore, the clinical findings do not completely substantiate this hypothesis as the results for infection by herpesviruses were negative and there were no antibodies for NMDA receptors or neuronal antigens in the CSF. Therefore, this case, and according to the criteria mentioned
Figure 3 – MRI in August 2019 showed reversal of imaging changes with increased peripheral cortical sulci, probably due to post encephalitis brain atrophy

Table 1 – Diagnostic criteria for negative-antibody probable encephalitis

<table>
<thead>
<tr>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Rapid progression (less than 3 months) of working memory deficits, altered mental state or psychiatric symptoms;</td>
</tr>
<tr>
<td>2. Exclusion of known syndromes of autoimmune encephalitis (e.g. ADEM typical limbic encephalitis)</td>
</tr>
<tr>
<td>3. Absence of antibodies in serum and CSF, and at least two of the following criteria:</td>
</tr>
<tr>
<td>- MRI findings suggestive of autoimmune encephalitis</td>
</tr>
<tr>
<td>- CSF pleocytosis or CSF-specific oligoclonal bands or elevated CSF IgG index</td>
</tr>
<tr>
<td>- Brain biopsy showing inflammatory infiltrates and excluding other causes</td>
</tr>
<tr>
<td>4. Exclusion of alternative etiologies</td>
</tr>
</tbody>
</table>

Only if all of the four criteria have been met, diagnosis can be made

ADEM: acute disseminated encephalomyelitis; MRI: magnetic resonance imaging; CSF: cerebrospinal fluid

above, presents a probable diagnosis of antibody negative AIE. Noteworthy, this is the best available diagnosis concerning this case, and is not a definitive one.

This case report presents limitations, particularly the fact that not all commercially available antibodies were tested (for example anti-Ri, anti-Yo, anti-CASPR2, anti-AMPA) and the screening in cells/tissues samples would be necessary for the definitive diagnosis of antibody negative autoimmune encephalitis.

Currently, the guidelines for diagnosis suggest that a complete antibody panel (intracellular, surface antigen and ion channels) should be done if there is a suspicion of AIE. Treatment for probable encephalitis is frequently given empirically prior to the results. In this case, acyclovir was given empirically for presumed HSE. The same reasoning can be used, prior to antibody results, with probable AIE, because clinical presentation and treatment response of antibody negative cases does not differ significantly from definitive AIE. Therefore, in suspected patients of AIE based on probable diagnosis, starting first line therapy, which consists of methylprednisolone, IVIG and/or plasmapheresis (there is no strong evidence of a difference in efficacy between IVIG and plasmapheresis), is recommended. First line immunotherapy can be given sequentially if no improvement is shown. In the absence of response, second line therapy should be started with rituximab or cyclophosphamide. The treatment should not be delayed since the evidence suggests early immunotherapy is associated with favourable outcomes and better prognosis.

PROTECTION OF HUMANS AND ANIMALS

The authors declare that the procedures were followed according to the regulations established by the Clinical Research and Ethics Committee and to the 2013 Helsinki Declaration of the World Medical Association.

DATA CONFIDENTIALITY

The authors declare having followed the protocols in use at their working center regarding patients’ data publication.
CASO CLÍNICO

André Ribeirinho MARQUES, António ALHO, João Malhadas MARTINS, Margarida BAIRRÃO


COMPETING INTERESTS

The authors have declared that no competing interests exist.

REFERENCES

PATIENT CONSENT

Obtained.

FUNDING SOURCES

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Obtained.

André Ribeirinho MARQUES, António ALHO, João Malhadas MARTINS, Margarida BAIRRÃO


RESUMO

A cirurgia bariátrica é uma opção terapêutica no tratamento da obesidade em doentes cuidadosamente selecionados, com perturbação psiquiátrica. Cerca de metade dos doentes referenciados para cirurgia bariátrica têm diagnosticada, pelo menos, uma perturbação mental, estando a maioria medicada com psicofármacos. Este procedimento pode alterar significativamente a biodisponibilidade dos fármacos e o lítio não é exceção. Contudo, apesar da absorção parecer diminuir na maioria dos fármacos, no caso do lítio existe um elevado risco de toxicidade. Neste artigo, descreve-se o caso de uma doente de 44 anos com um quadro de intoxicação por lítio após cirurgia bariátrica. Realizou-se uma revisão dos casos clínicos descritos na literatura de toxicidade ao lítio após cirurgia bariátrica e apresentam-se potenciais soluções clínicas preventivas. É essencial a maior consciencialização das alterações na absorção dos psicofármacos pós-cirúrgicos, particularmente no caso do lítio. Recomenda-se fortemente uma monitorização, de forma mais regular, pós-cirúrgica clínica e laboratorial dos níveis séricos de lítio.

Palavras-chave: Cirurgia Bariátrica; Lítio/efeitos adversos; Lítio/intoxicação

ABSTRACT

Bariatric surgery is a therapeutic option to treat obesity in (carefully selected) patients with psychiatric disorders. About half of the patients referred for bariatric surgery have a diagnosis of (at least one) mental disorder and most of them are treated with psychotropic drugs. This procedure may modify the bioavailability of drugs and lithium is no exception. However, although absorption seems to decrease in most drugs, in the case of lithium, there is a high risk of toxicity. In this article, we describe the case of a 44-year-old female patient with lithium intoxication after bariatric surgery. We conducted a review of the published clinical cases in the scientific literature about lithium toxicity after bariatric surgery, and we propose potential preventive clinical solutions. It is essential to increase awareness of changes to the absorption of psychotropic drugs in the post-surgery period, particularly in the case of lithium. Regular postoperative clinical and laboratory monitoring of lithium serum levels is strongly recommended.

Keywords: Bariatric Surgery; Lithium/adverse effects; Lithium/poisoning

2. Autor correspondente: André Ribeirinho Marques. andrthereibi@hotmail.com
4. Copyright © Ordem dos Médicos 2021
5. Lithium Intoxication after Bariatric Surgery: A Case Report

Lithium Intoxication after Bariatric Surgery: A Case Report

André Ribeirinho MARQUES, António ALHO, João Malhadas MARTINS, Margarida BAIRRÃO


ABSTRACT

Bariatric surgery is a therapeutic option to treat obesity in (carefully selected) patients with psychiatric disorders. About half of the patients referred for bariatric surgery have a diagnosis of (at least one) mental disorder and most of them are treated with psychotropic drugs. This procedure may modify the bioavailability of drugs and lithium is no exception. However, although absorption seems to decrease in most drugs, in the case of lithium, there is a high risk of toxicity. In this article, we describe the case of a 44-year-old female patient with lithium intoxication after bariatric surgery. We conducted a review of the published clinical cases in the scientific literature about lithium toxicity after bariatric surgery, and we propose potential preventive clinical solutions. It is essential to increase awareness of changes to the absorption of psychotropic drugs in the post-surgery period, particularly in the case of lithium. Regular postoperative clinical and laboratory monitoring of lithium serum levels is strongly recommended.

Keywords: Bariatric Surgery; Lithium/adverse effects; Lithium/poisoning

2. Autor correspondente: André Ribeirinho Marques. andrthereibi@hotmail.com
4. Copyright © Ordem dos Médicos 2021
5. Lithium Intoxication after Bariatric Surgery: A Case Report

Lithium Intoxication after Bariatric Surgery: A Case Report

André Ribeirinho MARQUES, António ALHO, João Malhadas MARTINS, Margarida BAIRRÃO


ABSTRACT

Bariatric surgery is a therapeutic option to treat obesity in (carefully selected) patients with psychiatric disorders. About half of the patients referred for bariatric surgery have a diagnosis of (at least one) mental disorder and most of them are treated with psychotropic drugs. This procedure may modify the bioavailability of drugs and lithium is no exception. However, although absorption seems to decrease in most drugs, in the case of lithium, there is a high risk of toxicity. In this article, we describe the case of a 44-year-old female patient with lithium intoxication after bariatric surgery. We conducted a review of the published clinical cases in the scientific literature about lithium toxicity after bariatric surgery, and we propose potential preventive clinical solutions. It is essential to increase awareness of changes to the absorption of psychotropic drugs in the post-surgery period, particularly in the case of lithium. Regular postoperative clinical and laboratory monitoring of lithium serum levels is strongly recommended.

Keywords: Bariatric Surgery; Lithium/adverse effects; Lithium/poisoning

2. Autor correspondente: André Ribeirinho Marques. andrthereibi@hotmail.com
4. Copyright © Ordem dos Médicos 2021